About Us

AmpliPhi Biosciences Corporation (AmpliPhi) is a biotechnology company dedicated to the development of innovative antibacterial solutions to improve human health through the application of its proprietary bacteriophage platform. 
 
Our lead product development programs target Gram negative bacterial infections that are often resistant to existing antibiotic treatments. They include BioPhage-PA for the treatment of chronic inner ear infections and BioPhage-PR, for the treatment of lung infections in cystic fibrosis patients.

AmpliPhi is also exploring product development opportunities to combine bacteriophage-based therapeutics with conventional antibiotics and develop multi-target, indication-specific therapeutics through the application of its bacteriophage technology and its established and expanding phage bank applicable to a range of bacterial targets.

AmpliPhi has secured multiple research grants to support portions of its product development programs. These include grant funding from the Cystic Fibrosis Foundation of America to support clinical trials of BioPhage-PR.

AmpliPhi maintains operations in Seattle, Washington and in Colworth Science Park, near London in the United Kingdom.